AlphAIAlphAI — Financial news for AI agents
investing.comOCT 132 min read$GOSS

Chardan initiates Gossamer Bio stock with buy on PAH therapy potential

Chardan initiated coverage on Gossamer Bio (NASDAQ:GOSS) with a Buy rating and $160 price target, citing potential FDA approval of seralutinib for PAH therapy. The stock is near its 52-week low at $9.28. The company has a market cap of $56.76M and faces an NDA decision in Q4 2026. Chardan estimates $1.3B in 2035 revenue if approved. Gossamer recently submitted an NDA for seralutinib, supported by clinical trial data. Leerink and H.C. Wainwright also issued positive ratings.

Original reporting
investing.com
Published Oct 13, 2026, 7:52 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 8:22 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$GOSS
Bullish
high confidence
Mentioned
$GOSS
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$GOSSBullishMed
01

Why it matters

The NDA submission represents the first formal regulatory request for seralutinib, turning pre‑clinical optimism into a concrete regulatory milestone. Analyst upgrades and a high price target reflect market belief in upside potential, but the company’s cash burn remains a concern.

02

Market read

The FDA NDA filing and analyst upgrades provide a fresh catalyst for GOSS, offering a potential short‑term trade idea for biotech‑focused investors.

03

What to watch

The company's limited cash runway and reliance on a single product candidate increase execution risk.

Relevance 7/10Novelty 8/10Timing: today

Background

Gossamer Bio (NASDAQ:GOSS) is a micro‑cap biotech developing seralutinib for pulmonary arterial hypertension. The company recently completed a private placement and is seeking FDA approval.

Company-level read

Ticker impact

$GOSSBullishHigh confidence
Context

Gossamer Bio submitted its first NDA to the FDA for seralutinib, a pulmonary arterial hypertension therapy, and received analyst upgrades with a $160 price target.

Expected impact

likely upward pressure as investors price in potential approval and higher valuation

Evidence & confidence

First FDA filing for a micro‑cap biotech is a material catalyst; upgrades reinforce upside expectations.

Market effects

Sector

May lift sentiment for other PAH‑focused biotech stocks and small‑cap pharma sector.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minimal global impact beyond niche biotech community.

Counterpoint

What could challenge this read

If the FDA imposes a complete response letter, the stock could sharply decline given its cash burn.

Key entities

  • company
    Gossamer Bio Inc.

    Biotech developer of seralutinib, subject of the article.

  • analyst
    Chardan

    Initiated coverage with a Buy rating and $160 target.

  • analyst
    Leerink

    Upgraded GOSS to Outperform.

Read at source← All news

Related articles

SEP 23
$GOSSMedAI 8/10

Gossamer Bio (GOSS) Files NDA for Seralutinib Amidst Challenging

Gossamer Bio (GOSS) filed an NDA for seralutinib, its treatment for pulmonary arterial hypertension. The submission is based on clinical data from the PROSERA and TORREY studies, though the PROSERA trial did not meet its primary endpoint. GOSS trades at a P/S ratio of 0.62, below its historical median and industry averages, reflecting market skepticism. The company has a GF Score of 22/100, indicating significant financial and operational challenges.

gurufocus.com2 min
SEP 23
$GOSSHighAI 8/10

Gossamer Bio stock rises on FDA filing for PAH drug

Gossamer Bio (GOSS) shares rose 3.7% after-hours after submitting a New Drug Application for seralutinib, a treatment for pulmonary arterial hypertension, to the FDA. The submission is backed by Phase 3 and Phase 2 study data. The FDA will decide whether to accept the application for review later this year.

investing.com2 min
SEP 23
$GOSSMedAI 8/10

Gossamer Bio, Inc. announced that it submitted a New Drug Application to the U.S. Food and Drug Administration in September 2026 for seralutinib for the…

Gossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 23, 2026, Gossamer Bio, Inc. (the “Company”) announced that it submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in September 2026 for seralutinib for the treatment of pulmonary arterial hypertension (“P

SEC EDGAR 8-K2 min
AUG 27
$GOSSMedAI 8/10

Gossamer (GOSS) Announced Up to $250M of Financing, but Only $25M is Expected Upfront. Is the Runway Secure?

Gossamer Bio (GOSS) announced a private placement with up to $250M in gross proceeds, but only $25M is expected upfront. The remaining funds are contingent on regulatory milestones for seralutinib, a drug for pulmonary arterial hypertension. The company ended June with $57M in cash, expecting the initial $25M to improve near-term liquidity but not fully secure its runway.

insidermonkey.com3 min